| ［1］ |
Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2021，71（3）:209-249.
|
| ［2］ |
Rahman R，Simoes EJ，Schmaltz C，et al. Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study［J］. Cancer Med，2017，6（4）:874-880.
|
| ［3］ |
Valle JW，Kelley RK，Nervi B，et al. Biliary tract cancer［J］. Lancet，2021，397（10272）:428-444.
|
| ［4］ |
Rawla P，Sunkara T，Thandra KC，et al. Epidemiology of gallbladder cancer［J］. Clin Exp Hepatol，2019，5（2）:93-102.
|
| ［5］ |
Hickman L，Contreras C. Gallbladder cancer: diagnosis，surgical management，and adjuvant therapies［J］. Surg Clin North Am，2019，99（2）:337-355.
|
| ［6］ |
Yoo C，Han B，Kim HS，et al. Multicenter phase Ⅱ study of oxaliplatin，irinotecan，and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer［J］. Cancer Res Treat，2018，50（4）:1324-1330.
|
| ［7］ |
Sharma A，Dwary AD，Mohanti BK，et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study［J］. J Clin Oncol，2010，28（30）:4581-4586.
|
| ［8］ |
Lee YT，Tan YJ，Oon CE. Molecular targeted therapy: treating cancer with specificity［J］. Eur J Pharmacol，2018，834:188-196.
|
| ［9］ |
Oh DY，Bang YJ. HER2-targeted therapies-a role beyond breast cancer［J］. Nat Rev Clin Oncol，2020，17:33-48.
|
| ［10］ |
Leal P，García P，Sandoval A，et al. Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma［J］. Arch Pathol Lab Med，2013，137（4）:552-557.
|
| ［11］ |
Song X，Hu Y，Li Y，et al. Overview of current targeted therapy in gallbladder cancer［J］. Signal Transduct Target Ther，2020，5（1）:230.
|
| ［12］ |
Kim RD，Chung V，Alese OB，et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer［J］. JAMA Oncol，2020，6（6）:888-894.
|
| ［13］ |
Trabucco SE，Gowen K，Maund SL，et al. A novel next-generation sequencing approach to detecting microsatellite instability and pantumor characterization of 1000 microsatellite instability-high cases in 67，000 patient samples［J］. J Mol Diagn，2019，21（6）:1053-1066.
|
| ［14］ |
Silva VW，Askan G，Daniel TD，et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency［J］. Chin Clin Oncol，2016，5（5）:62.
|
| ［15］ |
Lin J，Cao Y，Yang X，et al. Mutational spectrum and precision oncology for biliary tract carcinoma［J］. Theranostics，2021，11（10）:4585-4598.
|
| ［16］ |
Kassab J，Saba L，Gebrael G，et al. Update on immunotherapy in the management of gallbladder cancer［J］. Immunotherapy，2023，15（1）:35-42.
|
| ［17］ |
Naidoo J，Page DB，Li BT，et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies［J］. Ann Oncol，2015，26（12）:2375-2391.
|
| ［18］ |
Champiat S，Lambotte O，Barreau E，et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper［J］. Ann Oncol，2016，27（4）:559-574.
|
| ［19］ |
Guo Y，Feng K，Liu Y，et al. Phase Ⅰ study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers［J］. Clin Cancer Res，2018，24（6）:1277-1286.
|
| ［20］ |
Rojas-Sepúlveda D，Tittarelli A，Gleisner MA，et al. Tumor lysatebased vaccines: on the road to immunotherapy for gallbladder cancer［J］. Cancer Immunol Immunother，2018，67（12）:1897-1910.
|
| ［21］ |
Kobayashi M，Sakabe T，Abe H，et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer［J］. J Gastrointest Surg，2013，17（9）:1609-1617.
|
| ［22］ |
Vermeulen Z，Segers VFM，De Keulenaer GW. ErbB2 signaling at the crossing between heart failure and cancer［J］. Basic Res Cardiol，2016，111（6）:60.
|
| ［23］ |
Iqbal N，Iqbal N. Human epidermal growth factor receptor 2 （HER2）in cancers: overexpression and therapeutic implications［J］. Mol Biol Int，2014: 852748.
|
| ［24］ |
Mishra R，Patel H，Alanazi S，et al. HER3 signaling and targeted therapy in cancer［J］. Oncol Rev，2018，12（1）:355.
|
| ［25］ |
Lenferink AE，Busse D，Flanagan WM，et al. ErbB2/neu kinase modulates cellular p27（Kip1） and cyclin D1 through multiple signaling pathways［J］. Cancer Res，2001，61（17）:6583-6591.
|
| ［26］ |
Nam AR，Kim JW，Cha Y，et al. Therapeutic implication of HER2 in advanced biliary tract cancer［J］. Oncotarget，2016，7（36）:58007-58021.
|
| ［27］ |
Inagaki C，Maeda D，Kimura A，et al. Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: a case report［J］.World J Gastrointest Oncol，2019，11（9）:761-767.
|
| ［28］ |
Prieto M，Gastaca M，Ruiz P，et al. Long term recurrence free survival in a stage Ⅳ gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection［J］. Ann Hepatobiliary Pancreat Surg，2019，23（4）:403-407.
|
| ［29］ |
Ramanathan RK，Belani CP，Singh DA，et al. A phase Ⅱ study of lapatinib in patients with advanced biliary tree and hepatocellular cancer［J］. Cancer Chemother Pharmacol，2009，64（4）:777-783.
|
| ［30］ |
Harding JJ，Piha-Paul SA，Shah RH，et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers［J］. Nat Commun，2023，14（1）:630.
|
| ［31］ |
Hadi R，Pant MC，Husain N，et al. EGFR and HER-2/neu expression in gallbladder carcinoma: an institutional experience［J］. Gulf J Oncolog，2016，1（20）:12-19.
|
| ［32］ |
Mody K，Strauss E，Lincer R，et al. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report［J］. BMC Cancer，2010，10:570.
|
| ［33］ |
Philip PA，Mahoney MR，Allmer C，et al. Phase Ⅱ study of erlotinib in patients with advanced biliary cancer［J］. J Clin Oncol，2006，24（19）:3069-3074.
|
| ［34］ |
Xu D，Li J，Jiang F，et al. The effect and mechanism of vascular endothelial growth factor （VEGF） on tumor angiogenesis in gallbladder carcinoma［J］. Iran J Public Health，2019，48（4）:713-721.
|
| ［35］ |
Zhu AX，Meyerhardt JA，Blaszkowsky LS，et al. Efficacy and safety of gemcitabine，oxaliplatin，and bevacizumab in advanced biliarytract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study［J］. Lancet Oncol，2010，11（1）:48-54.
|
| ［36］ |
Peluso I，Yarla NS，Ambra R，et al. MAPK signalling pathway in cancers: olive products as cancer preventive and therapeutic agents［J］. Semin Cancer Biol，2019，56: 185-195.
|
| ［37］ |
Santarpia L，Lippman SM，El-Naggar AK. Targeting the MAPKRAS-RAF signaling pathway in cancer therapy［J］. Expert Opin Ther Targets，2012，16（1）:103-119.
|
| ［38］ |
Kazmi HR，Chandra A，Nigam J，et al. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer［J］. Dig Surg，2013，30（3）:233-239.
|
| ［39］ |
Li M，Chen L，Qu Y，et al. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing［J］. Oncotarget，2017，8（22）:36319-36330.
|
| ［40］ |
Giannini I，Cutrignelli DA，Resta L，et al. Metastatic melanoma of the gallbladder: report of two cases and a review of the literature［J］.Clin Exp Med，2016，16（3）:295-300.
|
| ［41］ |
Shu YJ，Weng H，Ye YY，et al. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway［J］.Mol Cancer，2015，14（1）:12.
|
| ［42］ |
Costello BA，Borad MJ，Qi Y，et al. Phase Ⅰ trial of everolimus，gemcitabine and cisplatin in patients with solid tumors［J］. Invest New Drugs，2014，32（4）:710-716.
|
| ［43］ |
Hwang IG，Jang JS，Do JH，et al. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients［J］. Cancer Chemother Pharmacol，2011，68（4）:935-944.
|
| ［44］ |
Kim Y，Bang SS，Jee S，et al. Prevalence and clinicopathological significance of MET overexpression and gene amplification in patients with gallbladder carcinoma［J］. Cancer Res Treat，2020，52（2）:481-491.
|
| ［45］ |
Li M，Liu F，Zhang F，et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer:a whole-exome sequencing analysis［J］. Gut，2019，68（6）:1024-1033.
|
| ［46］ |
王健东，全志伟. 重视胆道恶性肿瘤化疗联合靶向免疫的综合治疗［J/OL］. 中华肝脏外科手术学电子杂志，2023，12（2）:125-130.
|